ozempic and wegovy are both semaglutide. same molecule, different doses, different fda labels. ozempic is approved for type 2 diabetes (max 2.0 mg weekly). wegovy is approved for chronic weight management (max 2.4 mg weekly). rybelsus is oral semaglutide, approved for diabetes only. compounded semaglutide is the same compound at custom doses.
the differences are commercial and regulatory, not pharmacological. one molecule, three brand names, four fda indications, several insurance ladders, and a 503B compounding loophole that the fda is currently trying to close. this page lays out which is which.
they're the same compound.
semaglutide is a 31-amino-acid peptide. synthetic analog of glucagon-like peptide-1, modified at two residues for protease resistance and conjugated to a fatty acid for albumin binding. half-life ~7 days, which is why it's a once-weekly injection.
the active pharmaceutical ingredient in every novo nordisk semaglutide product is structurally identical. the molecule is the same across ozempic, wegovy, rybelsus, and compounded versions. the dose, the device, and the fda-approved indication are what differ.
a regulatory fork.
ozempic was fda-approved in december 2017 for type 2 diabetes. wegovy was fda-approved in june 2021 for chronic weight management. novo nordisk filed them as two brands rather than one, for reasons that are partly medical, partly commercial.
medical reason. the wegovy approval required a higher max dose (2.4 mg vs ozempic's 2.0 mg) and a different titration schedule. trial endpoints were different. it was cleaner to file as a separate product than to amend the ozempic label.
commercial reason. insurance companies treat diabetes drugs and obesity drugs differently. ozempic for diabetes is reimbursed widely. wegovy for obesity is gated by BMI cutoffs and prior auths. keeping them as separate brands lets novo charge different list prices and fight different insurance battles for each indication.
the two pens look slightly different too. wegovy's pen is single-use, pre-filled, color-coded by dose. ozempic's pen is multi-dose. but the drug inside is semaglutide either way.
the 0.4 mg gap matters.
ozempic dose ladder: 0.25 mg → 0.5 mg → 1.0 mg → 2.0 mg weekly. titration is 4 weeks per step.
wegovy dose ladder: 0.25 mg → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly. one extra step (1.7 mg) and a higher ceiling.
the 0.4 mg gap between max ozempic (2.0 mg) and max wegovy (2.4 mg) is small in absolute terms but meaningful in trial outcomes. semaglutide effects are dose-dependent. STEP 1 (NEJM 2021) tested 2.4 mg and reported 14.9% body weight loss. SUSTAIN 6 (NEJM 2016) tested 0.5-1.0 mg in T2D and reported far smaller weight effects.
prescribers occasionally use ozempic off-label for weight loss at the 2.0 mg dose. the practical efficacy is between SUSTAIN 6 and STEP 1, closer to STEP. but the 2.0 mg ozempic ceiling on the diabetes label sits below the wegovy dose ceiling.
what each one is approved for.
ozempic. type 2 diabetes mellitus (glycemic control). reduction of major adverse cardiovascular events in adults with T2D and established cardiovascular disease (added 2020 based on SUSTAIN 6).
wegovy. chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. reduction of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight (added march 2024 based on SELECT, NEJM 2023).
rybelsus. type 2 diabetes mellitus. oral once-daily formulation. diabetes-only label.
the SELECT label addition is significant. it gave wegovy a non-cosmetic medical indication for the first time, which started shifting insurance coverage. cardiologists can prescribe wegovy for cardiovascular risk reduction even outside the strict obesity criteria.
the oral version.
rybelsus is semaglutide in a tablet. fda-approved for type 2 diabetes only. the oral bioavailability of semaglutide is roughly 1%, so doses are far higher: 3, 7, or 14 mg daily. the absorption enhancer (SNAC, sodium N-(8-(2-hydroxybenzoyl)amino)caprylate) is what makes oral delivery viable.
weight loss on rybelsus is smaller than injectable semaglutide. PIONEER 4 (lancet 2019) reported ~4-5% body weight loss at 14 mg daily over 52 weeks vs 14.9% at 2.4 mg weekly injectable in STEP 1. the oral form is convenient but pharmacologically weaker for weight management.
novo is in late-stage trials of a higher-dose oral semaglutide (25 mg, 50 mg) targeted at obesity. OASIS-1 (2023) showed ~15% body weight loss at 50 mg daily, comparable to injectable wegovy. fda decision pending.
list prices and insurance.
wholesale acquisition cost (WAC), may 2026, US, no insurance:
with insurance, wegovy for obesity is variably covered. medicare doesn't cover anti-obesity drugs as a class (with limited exceptions for cardiovascular risk reduction post-SELECT). commercial plans vary widely. some require BMI ≥35, prior failure on lifestyle programs, or prior auth.
ozempic for diabetes is broadly covered. ozempic prescribed off-label for weight loss usually isn't.
novo's NovoCare direct cash-pay program drops wegovy to $499/month (relaunched march 2025 down from the earlier $650 tier), and Wegovy HD 7.2 mg has shipped at roughly $399/month via GoodRx since april 2026. stocking varies.
compounded semaglutide and the 503B fight.
through 2023-2024, the FDA's drug shortage list included semaglutide. that triggered a rule allowing 503B outsourcing facilities and 503A compounding pharmacies to produce compounded semaglutide legally. compounded versions are sold at $200-400/month, well below brand list prices.
the FDA removed semaglutide from the shortage list in february 2025. compounding under the shortage exception ended. the industry shifted to "personalized" or "patient-specific" formulations to keep selling compounded semaglutide under different regulatory carve-outs.
on april 30, 2026, the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. if finalized, that would close most 503B compounded-GLP-1 pathways (503A single-patient prescriptions stay legal under separate authority). the comment period runs through june 29, 2026. industry response has been intense.
bottom line: compounded semaglutide is the same molecule, but supply chain and quality control vary by pharmacy. the regulatory ground is moving under the entire compounded GLP-1 market right now.
how ozempic and wegovy split by indication.
the FDA-label answer depends on indication. this is label context, not personal guidance.
type 2 diabetes label: ozempic. it's approved, covered, and the trial evidence (SUSTAIN program) is targeted at glycemic outcomes. weight loss is a side effect, not the primary endpoint.
obesity label: wegovy. it's indicated for obesity (BMI ≥30) or overweight (BMI ≥27) with weight-related comorbidity. wegovy reaches the higher 2.4 mg dose, which is what the STEP 1 14.9% body weight loss number is based on.
cardiovascular label: wegovy is now indicated for MACE reduction in people with established cardiovascular disease and obesity or overweight (post-SELECT). this is also the cleaner insurance argument in 2026 since the cardiovascular benefit is FDA-recognized.
coverage failure: the market conversation broadens to compounded semaglutide (with the regulatory caveats above), tirzepatide (zepbound, comparably priced, higher efficacy in SURMOUNT-1), or oral semaglutide once novo's high-dose oral wegovy clears FDA review.
questions people actually ask.
is ozempic the same as wegovy? the molecule is identical (semaglutide). the FDA labels, dose ceilings, and insurance pathways are different. ozempic covers diabetes up to 2.0 mg. wegovy covers obesity up to 2.4 mg.
can i use ozempic for weight loss? off-label, prescribers do this. the 2.0 mg ceiling is below wegovy's 2.4 mg, so peak weight loss is somewhat lower. insurance won't cover ozempic for weight loss as the indication.
is rybelsus the same as ozempic? same molecule, oral instead of injectable. higher daily dose to compensate for ~1% bioavailability. weaker weight-loss effect. only approved for diabetes.
is compounded semaglutide as effective as wegovy? the molecule is identical. quality control depends on the compounding pharmacy. the FDA's april 2026 503B proposal would close most legal compounding pathways if finalized.
which is cheaper, ozempic or wegovy? ozempic list price is lower (~$936 vs ~$1,349/month). but if your insurance covers wegovy and not ozempic for your indication, wegovy is cheaper out of pocket.
can you switch from ozempic to wegovy? yes, with a prescriber. titration usually doesn't reset since you're moving up within the same molecule. patients on max ozempic (2.0 mg) typically transition to wegovy 2.4 mg directly.
what about tirzepatide vs semaglutide? different molecule. semaglutide vs tirzepatide covers the head-to-head. short version: tirzepatide (mounjaro/zepbound) is dual GIP/GLP-1, hits higher published weight loss in SURMOUNT-1 (22.5% vs 14.9%), shorter trial history.
reptides editorial · research reference, not medical advice.